Scarica l'app Stockscreener
13.48
2.46%
-0.34
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$13.82
Aprire:
$13.87
Volume 24 ore:
1.16M
Relative Volume:
0.42
Capitalizzazione di mercato:
$2.03B
Reddito:
-
Utile/perdita netta:
$-647.68M
Rapporto P/E:
-2.3774
EPS:
-5.67
Flusso di cassa netto:
$-594.49M
1 W Prestazione:
-5.87%
1M Prestazione:
-9.41%
6M Prestazione:
+13.95%
1 anno Prestazione:
-10.73%
Intervallo 1D:
$13.25
$13.94
Intervallo di 1 settimana:
$13.13
$14.89
Portata 52W:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
13.48 | 2.18B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-06 | Iniziato | Goldman | Buy |
| 2026-01-21 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Downgrade | UBS | Buy → Neutral |
| 2025-11-06 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Iniziato | Citigroup | Buy |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy - simplywall.st
Federal jury awards Yale University, Biohaven $4M in trade secret suit - Westfair Communications
Yale, Biohaven Win $4M In Biotech Trade Secret Trial - Law360
Why is Biohaven Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada
Yale, Biohaven Win $4 Million Verdict Over Drug-Development Tech - Bloomberg Law News
Federal jury awards Yale, Biohaven $4M in lawsuit over trade secrets - Hartford Business Journal
Biohaven and Yale win $4M verdict in trade secret case - Investing.com Nigeria
Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million - PR Newswire
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biohaven Ltd (BHVN) Institutional Confidence - TradingKey
Biohaven Ltd (BHVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biohaven Ltd (BHVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BHVN|Biohaven Ltd|Price:14.320|Chg%:-0.320 - TradingKey
BHVN|Biohaven Ltd|Price:14.563|Chg%:+0.243 - TradingKey
Biohaven Ltd (BHVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biohaven Ltd. Revenue Breakdown – NYSE:BHVN - TradingView
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 53% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven Pharmaceutical Holding Company Ltd (BHVN) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload - Finansavisen
How Biohaven’s (BHVN) R&D Leadership Shuffle Will Impact Investors - simplywall.st
Biohaven Ltd. (NYSE: BHVN) legal chief discloses holdings - Stock Titan
Lobbying Update: $120,000 of BIOHAVEN LTD. lobbying was just disclosed - Quiver Quantitative
Biohaven files Form 3 for Chief Legal Officer Warren Karl Volles - Bitget
Price to book forward of Biohaven Ltd. – NYSE:BHVN - TradingView
Discipline and Rules-Based Execution in BHVN Response - Stock Traders Daily
Biohaven (BHVN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Price to earnings forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs - TradingView
Biohaven: Nice Pipeline Momentum, But Its Runway Is A Risk (NYSE:BHVN) - Seeking Alpha
Enterprise value to EBIT forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Price to sales forward of Biohaven Ltd. – NYSE:BHVN - TradingView
Price to sales forward of Biohaven Ltd. – BOATS:BHVN - TradingView
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Co - GuruFocus
Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey - Sahm
Enterprise value to revenue forward of Biohaven Ltd. – NYSE:BHVN - TradingView
BHVN News | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven announces leadership changes - Hartford Business Journal
Biohaven Announces Scientific Leadership Changes - Contract Pharma
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership - Yahoo Finance
Is Biohaven’s (BHVN) R&D Shake-Up Quietly Redefining Its Late-Stage Pipeline Strategy? - Yahoo Finance
Biohaven Announces Scientific Leadership Transitions - GuruFocus
Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer - Moomoo
Biohaven: Bruce Car, Transitioning From Chief Scientific Officer to Chief Innovation Officer Focusing on External Collaborations >BHVN - Moomoo
Biohaven Announces Leadership Changes to Accelerate CNS Drug Discovery and Innovation Through Bexorg Collaboration – Minichart - Minichart
Biohaven announces leadership changes in discovery unit By Investing.com - Investing.com India
Biohaven announces leadership changes in discovery unit - Investing.com
Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head - Stock Titan
Biohaven (BHVN) Completes Enrollment in RISE3 Trial - Yahoo Finance
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Yahoo Finance
Janus Henderson holds 8.58M Biohaven shares (BHVN) — 5.7% stake - Stock Titan
Biohaven (BHVN) Is Up 5.6% After Advancing Two Late-Stage Trials in Epilepsy and Graves’ Disease - simplywall.st
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biohaven Ltd Azioni (BHVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Buten Matthew | Chief Financial Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,250 |
0 |
198,246 |
| Coric Vlad | Chief Executive Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
14,250 |
0 |
1,811,398 |
| Car Bruce | Chief Scientific Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,750 |
0 |
10,096 |
| Clark George C. | VP, Chief Accounting Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
68,095 |
| Clark George C. | VP, Chief Accounting Officer |
Nov 17 '25 |
Buy |
8.52 |
17,000 |
144,770 |
20,000 |
| Bailey Gregory | Director |
Nov 13 '25 |
Buy |
7.50 |
400,000 |
3,000,000 |
2,020,071 |
| CHILDS JOHN W | Director |
Nov 13 '25 |
Buy |
7.50 |
3,333,333 |
24,999,998 |
5,653,904 |
| Coric Vlad | Chief Executive Officer |
Nov 13 '25 |
Buy |
7.50 |
666,666 |
4,999,995 |
1,195,275 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):